Compare McKesson Corporation (MCK) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Charles Schwab Corporation Common Stock — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is the larger of the two by market cap, and Charles Schwab Corporation Common Stock pays the higher dividend (1.32%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| MCK | SCHW | |
|---|---|---|
Market Cap | $108.46B | $167.52B |
Volume | 712,607 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $995.69 | $113.65 |
52-Week Low | $725.17 | $85.35 |
Typical Hold Time | 74 Days | 85 Days |
Enterprise Value | $115.00B | $153.97B |
Dividend Yield | 0.4% | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Charles Schwab (SCHW) trades at $96.87, up 1.35% with strong fundamentals including 37% net margin and consistent earnings beats. Technical indicators show bearish momentum near key support at $96, while fundamentals reveal robust revenue growth to $23.92B in 2025 and improving cash flow. The company demonstrates operational strength with client assets reaching $13.41T in August 2026 and strategic AI integration with Anthropic.
Outlook remains positive with 56.9% analyst buy ratings and $120.33 consensus target, though near-term technical weakness and competitive pressures pose risks. Earnings momentum and market share gains in the growing e-brokerage sector support upside potential, while interest rate sensitivity and execution risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
